EFFICACY AND SAFETY OF MULTI-TARGETED KINASE INHIBITORS IN PROGRESSIVE, RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCERS: A META-ANALYSIS

  • Mutahir A Tunio Comprehensive Cancer Center, King Fahad Medical City, Riyadh
  • Mushabbab AlAsiri
  • Yasser Bayoumi

Abstract

Purpose: A meta-analysis was conducted to evaluate the impact of oral multitargeted kinase inhibitors (MTKIs) in radioactive-iodine refractory locally advanced, recurrent/metastatic differentiated thyroid cancer (DTC) on disease control rate (DCR), progression-free survival (PFS) and overall survival (OS) rates.

Materials and Methods: The PubMed/MEDLINE, CANCERLIT, EMBASE, Cochrane Library database and other search engines were searched to identify randomised controlled trials (RCTs) comparing MTKIs with placebo in locally advanced, recurrent/metastatic DTC. Pooled data were expressed as odds ratio (OR), with 95% con dence intervals (CIs, Mantel–Haenszel xed-effect model).

Results: Three RCTs with a total patient population of 954 patients were identi ed. The use of MTKIs was associated with improved PFS (OR: 0.262, 95% CI: 0.19–0.35; heterogeneity (I2) = 22.4%; P < 0.0001), improved DCR (complete and partial responses + stable disease, P < 0.0001) and improved OS 0.66, 95% CI: 0.46–0.96 (I2 = 43%, P = 0.034). Lenvatinib (compliance = 87%) was associated with more grade ≥3 hypertension. However, its other adverse effects were much lower than sorafenib (compliance = 56%) and vandetanib.

Conclusion: In radioactive iodine-refractory recurrent, metastatic DTC patients, lenvatinib and sorafenib were associated with improved PFS, DRC and OS rates, while the compliance was better with lenvatinib.

Key words: Meta-analysis, multitargeted kinase inhibitors, progressive differentiated thyroid cancer, radioactive iodine- refractory 

References

Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012;166:5-11.

Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: Bene ts and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91:2892-9.

Shoup M, Stojadinovic A, Nissan A, et al. Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma. J Am Coll Surg 2003;197:191-7.

Shimaoka K, Schoenfeld DA, DeWys WD, et al. A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma. Cancer 1985;56:2155-60.

Kundra P, Burman KD. Thyroid cancer molecular signaling pathways and use of targeted therapy. Endocrinol Metab Clin North Am 2007;36:839-53.

Gallo M, Michelon F, Castiglione A, et al. Sorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: A cohort study from a single centre. Endocrine 2015;49:726-34.

Cabanillas ME, Schlumberger M, Jarzab B, et al. A phase 2 trial of lenvatinib (E7080) in advanced, progressive, radioiodine refractory, differentiated thyroid cancer: A clinical outcomes and biomarker assessment. Cancer 2015;121:2749-56.

Begg CB, Mazumdar M. Operating characteristics of rank correlation test for publication bias. Biometrics 1994;50:1088-101.

Egger M, Smith GD, Schneider M, et al. Bias in meta- analysis detected by a simple graphical test. BMJ 1997;315:629-34.

Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13:897-905.

Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: A randomised, double-blind, phase 3 trial. Lancet 2014;384:319-28.

Schlumberger M, Tahara M, Wirth LJ, et al. Lenvatinib versus placebo in radioiodine- refractory thyroid cancer. N Engl J Med 2015;372:621-30.

Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: Results of a phase 2 consortium study. Lancet Oncol 2010;11:962-72.

Cohen EE, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: Results from a phase II study. J Clin Oncol 2008;26:4708-13.

ShermanSI,WirthLJ,DrozJP,etal.Motesanibdiphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359:31-42.

Lawrence TS, Nyati MK. Small-molecule tyrosine kinase inhibitors as radiosensitizers. Semin Radiat Oncol 2002;12:33-6.

Hesselink EN, Steenvoorden D, Kapiteijn E, et al. Therapy of endocrine disease: Response and toxicity of small- molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: A systematic review and meta-analysis. Eur J Endocrinol 2015;172:R215-25.

Published
2016-05-05
How to Cite
1.
Tunio MA, AlAsiri M, Bayoumi Y. EFFICACY AND SAFETY OF MULTI-TARGETED KINASE INHIBITORS IN PROGRESSIVE, RADIOIODINE-REFRACTORY DIFFERENTIATED THYROID CANCERS: A META-ANALYSIS. J Cancer Allied Spec [Internet]. 2016May5 [cited 2020Aug.15];2(1). Available from: https://journals.sfu.ca/jcas/index.php/jcas/article/view/50